ஃபைப்ரோபிளாஸ்ட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஃபைப்ரோபிளாஸ்ட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஃபைப்ரோபிளாஸ்ட் Today - Breaking & Trending Today

COVID-19 may alter host proteins to cause autoimmunity


COVID-19 may alter host proteins to cause autoimmunity
To better understand the transient and chronic autoimmune symptoms caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, researchers from Memorial Sloan Kettering Cancer Center, Guizhou Medical University, and biotech company Curandis embarked on an endeavor to establish a comprehensive autoantigenome for COVID19.
In a previous study, the team identified a repertoire of autoantigens (autoAgs) from human fetal lung fibroblast HFL1 cells strongly tied to neurological and diverse autoimmune symptoms COVID19.
In the current study, they aimed to identify more autoAgs from A549 cells, which are human lung epithelium-like cells, derived from adenocarcinoma cells used to model SARS-CoV-2 infection. ....

Liji Thomas , Guizhou Medical University , Memorial Sloan Kettering Cancer Center , Antiphospholipid Syndrome , Binding Affinity , Cell Signaling , Corona Virus , Coronavirus Disease Covid 19 , Immune Response , Protein Expression , Sars Cov 2 , Severe Acute Respiratory , Severe Acute Respiratory Syndrome , நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம் , பிணைப்பு இன உறவு , செல் சமிக்ஞை , கொரோனா வைரஸ் , நோய் எதிர்ப்பு சக்தி பதில் , ப்ரோடீந் வெளிப்பாடு , கடுமையானது எடுப்போசை சுவாச , கடுமையானது எடுப்போசை சுவாச நோய்க்குறி ,

FibroGenesis Reports Positive Preclinical Data in Pancreatic and Breast Cancer Using Universal Acting Fibroblast Based Immunotherapy


(1)
Novel Approach Successfully Induces Regression of Established Tumors by Focusing Immunotherapy to Target Achilles Heel of Cancer
HOUSTON, Feb. 17, 2021 /PRNewswire/ FibroGenesis, a clinical stage company developing fibroblast-based therapeutic solutions for unmet medical needs, announced today new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer.
Company scientists successfully replicated the process by which cancer coaxes fibroblasts to support its growth. By manipulating these artificially generated cancer-associated-fibroblasts (CAFs) , the Company was able to generate an immunotherapy that teaches the immune system to selectively kill only fibroblasts which help tumors to grow. ....

United States , Pete Oheeron , Tom Ichim , Kostenloser Wertpapierhandel , Prnewswire Fibrogenesis , Novel Approach Successfully Induces Regression , Established Tumors , Nobel Prize , Chief Scientific Officer , Peteo Heeron , Disc Degeneration , Multiple Sclerosis , Chronic Traumatic Encephalopathy , Liver Failure , ஒன்றுபட்டது மாநிலங்களில் , நோபல் ப்ரைஸ் , தலைமை அறிவியல் அதிகாரி , வட்டு சீரழிவு , பல ஸ்க்லரோசிஸ் , கல்லீரல் தோல்வி , நோயெதிர்ப்பு சிகிச்சை ,

Study: Fibroblast hormone promotes movement of hematopoietic stem cells


Study: Fibroblast hormone promotes movement of hematopoietic stem cells
Discovery expected to contribute towards more effective methods of harvesting stem cells from bone marrow donors.
A Kobe University research group including graduate student ISHII Shinichi and Associate Professor KATAYAMA Yoshio (both of the Department of Hematology, Graduate School of Medicine) have discovered that fibroblast growth factor-23 (FGF23) produced by erythroblasts (cells that are the precursors of red blood cells) promotes the movement (mobilization) of hematopoietic stem cells into the peripheral blood.
Up until now, FGF23 has been known for the role it plays in the kidneys as a hormone that regulates phosphate concentrations throughout the body. ....

United States , Emily Henderson , Ya Kobe University , School Of Medicine , Department Of Hematology , Kobe University , Associate Professor , Graduate School , Bone Marrow , Bone Marrow Transplant , Growth Factor , Red Blood Cells , Stem Cells , ஒன்றுபட்டது மாநிலங்களில் , எமிலி ஹென்டர்சன் , பள்ளி ஆஃப் மருந்து , துறை ஆஃப் ஹீமாட்டாலஜி , கோபி பல்கலைக்கழகம் , இணை ப்ரொஃபெஸர் , பட்டதாரி பள்ளி , எலும்பு மஜ்ஜை , எலும்பு மஜ்ஜை மாற்று , வளர்ச்சி காரணி , சிவப்பு இரத்தம் செல்கள் , தண்டு செல்கள் ,

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials


MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials
The modified vaccina virus Ankara (MVA) is an attenuated vaccinia virus that has been used as a vector in the already approved Adenovirus-MVA-based Ebola vaccine. A new preprint appearing on the
bioRxiv server reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that is causing the current coronavirus disease 2019 (COVID-19) pandemic. The MVA provides a vector platform for the rapid production of such vaccines.
The current study demonstrates the expression of the full-length spike (S) glycoprotein antigen of the SARS-CoV-2 virus by the rMVA. The rMVA-spike-expressing viruses showed efficient replication in the chicken embryo fibroblast cell line DF-1, but not in the human cell lines. ....

Liji Thomas , Middle East , Coronavirus Disease Covid 19 , Sars Cov 2 , Vaccinia Virus , Cell Line , Corona Virus , Severe Acute Respiratory , Severe Acute Respiratory Syndrome , Spike Protein , நடுத்தர கிழக்கு , செல் வரி , கொரோனா வைரஸ் , கடுமையானது எடுப்போசை சுவாச , கடுமையானது எடுப்போசை சுவாச நோய்க்குறி , ஸ்பைக் ப்ரோடீந் ,